Progress and opportunities for women in clinical trials: A look at recent data and initiatives from the U.S. FDA.
Journal
Med (New York, N.Y.)
ISSN: 2666-6340
Titre abrégé: Med
Pays: United States
ID NLM: 101769215
Informations de publication
Date de publication:
14 05 2021
14 05 2021
Historique:
entrez:
19
5
2022
pubmed:
20
5
2022
medline:
24
5
2022
Statut:
ppublish
Résumé
Recruiting and retaining diverse populations in clinical research is critically important. Over the years, we have seen improvements in the representation of women in clinical trials submitted in FDA marketing applications, and we are encouraged by the potential for new strategies to further their representation.
Identifiants
pubmed: 35590224
pii: S2666-6340(21)00159-8
doi: 10.1016/j.medj.2021.04.010
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
456-459Informations de copyright
Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no conflicts of interest. The contents of this publication reflect the thoughts of the authors and do not represent the official views of, nor an endorsement by, the FDA, Department of Health and Human Services, or US government.